A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Circular RNA is edging toward a modality breakout - and Circio is one of the few players with early pharma validation.
circVec has shown up to 40× higher protein expression and ~75× longer RNA stability in vivo, tackling gene therapy’s core bottleneck: durable expression without vector overload.
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
The machinery that governs gene expression is being targeted to beat cancer.
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
If the disease is in the lungs, why deliver the drugs everywhere else?
